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Site-Specific Binding Constants for Actinomycin D on DNA Determined from
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We report site-specific binding constants for the intercalating anticancer drug actinomycin D
(Act-D), binding to a 139-base-pair restriction fragment from pBR 322 DNA. The binding constants are
derived from analysis of footprinting experiments, in which the radiolabeled 139-mer is cleaved using DNase
I, the cleavage products undergo gel electrophoresis, and, from the gel autoradiogram, spot intensities,
proportional to amounts of cleaved fragments, are measured. A bound drug prevents DNase I from cleaving
at -7 bonds, leading to decreased amounts of corresponding fragments. With the radiolabel on the 3’ end
of the noncoding strand (A-label), we measured relative amounts of 54 cleavage products at 25 Act-D
concentrations. For cleavage of the 139-mer with the label on the 3’ end of the coding strand (G-label),
relative amounts of 43 cleavage products at 11 Act-D concentrations were measured. These measurements
give information about 120 base pairs of the restriction fragment (- 12 turns of the D N A helix); in this
region, 14 strong and weak Act-D binding sites were identified. The model used to interpret the footprinting
plots is derived in detail. Binding constants for 14 sites on the fragment are obtained simultaneously. It
is important to take into account the effect of drug binding at its various sites on the local concentration
of probe elsewhere. It is also necessary to include in the model weak as well as strong Act-D sites on the
carrier DNA which is present, since the carrier DNA controls the free-drug concentration. As expected,
the strongest sites are those with the sequence (all sequences are 5’
3’) GC, with TGCT having the highest
binding constant, 6.4 X lo6 M-l. Sites having the sequence G C preceded by G are weak binding sites, having
binding constants approximately 1 order of magnitude lower than those of the strong sites. Also, the
non-GC-containing sequences CCG and CCC bind Act-D with a binding constant comparable to those of
the weak G G C sites. The analysis may reveal drug-induced structural changes on the DNA, which are
discussed in terms of the mechanism of Act-D binding.
ABSTRACT:

-

-

Actinomycin D, Act-D (Figure I), is one of the most intensely studied anticancer drugs (Gale et al., 1981). Numerous
investigations have shown that the agent exhibits its antitumor
effects by binding to double-stranded DNA, thereby blocking
transcription. The binding mechanism involves intercalation
of the phenoxazone ring system of the drug via the minor
groove of DNA at GC-rich sites (Gale et al., 1981).
Footprinting studies on Act-D using DNase I (Lane et al.,
1983; Scamrov & Beabealashvilli, 1983; Fox & Waring, 1984)
and Fe-MPE (van Dyke et al., 1982) showed that the highest
‘We acknowledge the American Cancer Society, Grant NP-681, for
supporting this research.

affinity sites have the dinucleotide sequence 5’-GC-3’. Model
building and a single-crystal X-ray structural analysis (Sobell
1973) indicated that the specificity of Act-D for this sequence
is due to hydrogen bonding between the 2-amino group of
guanine of DNA and the threonine moiety located in the cyclic
peptide of the drug.
Although 5’-GC-3’ is the preferred binding site, there are
other sites. The duplex d(CGTCGACG)*, which does not
contain 5’-GC-3’, is able to strongly bind two actinomycin D
molecules in a highly cooperative manner (Snyder et al., 1989).
Further, in an effort to measure Act-D binding specificity, Rill
et al. (1989) examined the DNA cleavage sites of the photoaffinity probe 7-azidoactinomycin D on several DNA re-
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2: The 139-base-pairfragment of pBR 322 DNA used in this
study. Actinomycin D binding sites are indicated by rectangles, filled
for strong sites and open for weak sites. Locations of the radiolabel:
for the A-labeled experiment, position 33; for the G-labeled experiment,
position 172.
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1: Structure of the drug actinomycin D.

striction fragments and found that GC doublets were strongly
preferred only if the 5’-flanking base was a pyrimidine and
the 3‘-flanking base was not cytosine. In addition, the central
GG doublet in the sequence TGGG is a strong Act-D site.
We have shown that binding constants for drugs on random
sequence DNA can be obtained by quantitative analysis of
footprinting data (Dabrowiak & Goodisman, 1989; Rehfuss
et al., 1990a,b; Dabrowiak et al., 1991). In the footprinting
experiment, we measure the amounts of the various fragments
produced by cleavage of a DNA polymer by a cleavage agent,
the “probe”, in the presence of various amounts of the drug.
The amount of fragment of a particular length is proportional
to the amount of cleavage at a particular position on DNA.
A plot of this quantity as a function of the amount of drug
present, called the “footprinting plot”, reflects the ability of
the drug molecule to inhibit (or, sometimes, enhance) cleavage
by the probe. To analyze these “footprinting plots”, one must
take into consideration overlapped drug sites, cleavage enhancements, and the way in which the drug affects cutting by
the probe. The analysis makes it possible to measure binding
constants for overlapping sites and, if measurements are made
at different temperatures, to obtain a full thermodynamic
profile of a drug: AGO, AH’,and ASo (Dabrowiak et al.,
1990).
The quantitative footprinting method is the only method
capable of giving simultaneousvalues for a number of binding
constants, corresponding to binding to different sites, and it
is a valuable tool in investigating sequence specificity, selectivity, and wperativity in drug binding to DNA. Knowledge
of these factors is important in the understanding of the
mechanism of action of drugs and is crucial to drug design.
In a previous report, we measured the binding constant of
Act-D toward a small oligonucleotide duplex containing the
sequence GCGC using DNase I footprinting (Rehfuss et al.,
1990a). In a preliminary study, we also analyzed the binding
of actinomycin D to a 139-base-pair fragment of pBR 322
DNA (Figure 2), using DNase I, Fe-MPE, and the cationic
porphyrin Mn-T4 as footprinting cleavage probes (Ward et
al., 1988; Rehfuss et al., 1990b). Our analysis focused on the
initial loading events on the 139-mer, for drug concentrations
from 0 to 7.64 pM, the upper limit corresponding to roughly
50% occupation of the strong sites by drug. We derived
equilibrium binding constants for the highest affinity sites and
discussed the ability of different probes to reveal drug-induced
structural changes on DNA.
In this report, we derive binding constants for both the highand low-affinity sites. We must ascertain whether the simple
model used so far is sufficient to explain the footprinting results
obtained for the complete range of actinomycin D concentrations or whether additional assumptions (such as drug-ind u d structural effects) must be made. We show below that

both high- and low-affinity sites on the carrier DNA must be
included in the model, even if one is interested in calculating
binding constants only for the high-affinity sites on the fragment. In addition, by considering drug concentrations lafge
enough to produce a liigh degree of drug loading on the DNA
fragment, we have an opportunity to detect drug-induced
structural changes in DNA, which have been previously reported to occur for Act-D (Fox & Waring, 1984; Huang et
al., 1988; Bishop et al., 1991).
MATERIALS
AND METHODS
The HindIIIINciI, 139-base-pair restriction fragment from
pBR 322 DNA was isolated, purified, and end-labeled for one
set of experiments at position 33(A), and for a second set of
experiments it was labeled at 172(G) with reverse transcriptase
as previously described (Lown et al., 1986; Bromley et al.,
1986). Figure 2 shows the sequence of this fragment, as well
as the drug-binding sites. The DNase I, obtained from Sigma
Chemical Co., was used without purification.
The DNase I footprinting experiments involving the 139-mer
and Act-D were carried out as previously described (Ward et
al., 1988). The photograph of the autoradiogram along with
the drug concentrations (from 0 to 38.8 pM) used in the
A-label experiment was published previously (Ward et al.,
1988). The experiments involving the G-labeled 139-mer were
carried out under conditions identical to those of the A-labeled
series except that only 10 drug concentrations were used,
having final values in the reaction medium of 2.48, 3.40,4.86,
6.93,9.89, 14.1,20.2, 28.8, 41.0, and 58.7 pM. The autoradiogram for the G-labeled experiment is shown in Figure 3.
All experiments were carried out in buffer, containing 50 mM
Tris-HC1,8 mM MgC12,and 2 mM CaC12,at pH 7.5, for 10
min. The final concentration of DNA in each of the reactions
was 194 pM base pairs: 193 pM base pairs sonicated calf
thymus DNA and 1 pM base pairs radiolabeled fragment.
Control reactions were carried out to determine the amount
of enzyme necessary to leave -70% of the fragment uncleaved
at the end of the digest time of 10 min (single-hit regime).
The autoradiograms resulting from both the A- and G-labeled
experiments were scanned with a microdensitometer/computer
system to yield cross-sectional areas of bands, proportional to
oligonucleotide concentrations (Dabrowiak et al., 1986). Plots
of spot intensity as a function of drug concentration for each
DNase I cleavage site (footprinting plots) were prepared in
the manner previously described (Dabrowiak & Goodisman,
1989). This involved using the “total-cut plot”, shown in
Figure 4 for the A-label experiment, to correct the data for
gel-loading errors and slightly different digest times.

-

THEORY:MODELFOR THE SYSTEM AND FOOTPRINTING
PLOTS
Binding of Act-D to the 139-mer. It is known that actinomycin D binds to DNA via the minor groove, mainly at
GC-rich sites (Gale et al., 1981). Our footprinting analysis
confirmed that the strongest binding sites on the polymer were
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quence 5’-GC-3‘ (the 5’-GGC-3’ sites are considered among
the weak sites in the present work). Furthermore, 5’-CCGT-3’,
which does not contain the classical GC-binding sequence,
appeared to be a binding site, with a binding constant comparable to that of the GGC sites.
The model used assumes that the drug bound to DNA
blocks the probe from binding and cutting in a region near
the position of the drug molecule. The actinomycin D molecule
“covers” about 4 base pairs, including the G, the C, and one
base pair on either side (Gale et al., 1981). Considering the
size and shape of DNase I (Suck et al., 1988), we conclude
that when an actinomycin molecule is bound at the GC site,
DNase I cannot cleave at sites from about 3 base pairs on the
3’ side of the GC to about 2 base pairs on the 5’ side. Thus,
the inhibition region for a single drug molecule is about 7 base
pairs in size; footprinting plots for all sites in such a region
should be identical, within a multiplying constant.
These footprinting plots show intensities monotonically
decreasing with drug concentration. Footprinting plots for
other sites show enhanced cutting, leveling off, and then further
enhancement of cutting as drug concentration is increased; we
assume that these are sites at which no drug binds. The
explanation for the enhancement is given below. Other plots
show initial increases of intensity with increased drug concentration and a subsequent intensity decrease. These are the
weaker binding sites, for which drug binds at a sufficiently
high drug concentration, causing a decrease in intensity which
overcomes the enhancement. At drug concentrations high
enough to cause binding at the weak binding sites on the
139-mer, weak-binding sites on the carrier DNA used in the
experiment must also accept the drug. Thus, the analysis of
footprinting data for higher drug concentrations requires
modification in the model previously used for quantitative
footprinting analysis of the initial loading events (strong
binding sites), to include the activity of weak sites on the
carrier DNA (Rehfuss et al., 1990b).
The equilibrium between drug bound at drug-binding site
i and free (unbound) drug is governed by the equilibrium
constant Ki, according to

v

-60

-90

-110

-120

-130

-1 4 0

-150

FIGURE 3: Autoradiogram for the G-labeled experiment. The Act-D
micromolar concentrations are shown at the top of each lane.

where Si is the concentration of sites i (equal to the concentration of DNA polymers), Di is the concentration of polymers
having drug bound at site i, and Do is the concentration of free
(unbound) drug. For cutting sites within the ith drug-binding
site, the probability that the probe can cut is thus determined
by
KiDo = ~ i / ( l - vi)
(2)
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FIGURE 4: Total-cut plot for the A-labeled experiment. The sum of
the spot intensities corresponding to 93% of all cleavage products is
plotted as a function of total drug concentration. The broken line
is a least-squares fit to a linear function; the ratio of this function
to the measured total cut multiplies all spot intensities for that drug
concentration to correct for gel loading and other errors.

5’-GC-3’, but the binding constant depended markedly on the
bases on either side of the GC (Rehfuss et al., 1990b; Ward
et al., 1988). In particular, sites having the sequence 5’GGC-3’ were much weaker than other sites having the se-

~

~

where vi is the fraction of DNA polymers having a drug bound
at drug-binding site i (and thus not cleavable at all sites in
a 7-base-pair inhibition region centered near site i). Do is
determined by equilibria like that given in eq 1 between free
drug and drug bound to sites on the labeled DNA and the
unlabeled calf thymus carrier DNA. Thus, the equation
ct =
KwDo
1x
KiDo
KCDO
KCDO
KwDo
139 ? i + KiDo
(3)
to be solved for Dofor each total drug concentration c,, by
successive iteration. Here, c, and c, are the concentrations
of strong and weak sites on the carrier, K, and K , are the
respective binding constants, and the concentration of any site
i on labeled fragment is the fragment concentration in base
pairs, 1 X lo”, divided by the number of sites per fragment.
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If carrier is present in large excess, c, and c, are probably much
larger than (1 X 104)/139, and equilibria with carrier dominate (eq 3).
Modeling the carrier would not be necessary if it consisted,
instead of calf thymus DNA, of unlabeled copies of the
fragment studied. The theoretical analysis would be simplified
(determination of c,, c,, K,, and K , would be unnecessary),
but one would have to have larger amounts of the fragment
and accurately determine its concentration. Most drug-DNA
footprinting experiments to date have not used unlabeled
fragment as the carrier.
The probability of cutting at a site near i, if the drug-binding
site is an isolated one, i.e., not overlapped with other drug sites,
is proportional to 1 - vi, which is equal to (1 KiD0)-l. If
the cleavage site is near two drug sites, j and k,so that drug
bound at either site will inhibit cleavage by DNase I, 1 - vi
is equal to [(l Kpo)(
1 KkDO)]-l.
This assumes that drug
binds independently at the two sites j and k. If the sites are
close enough together so that a drug molecule bound at one
prevents drug from binding at the other but that a drug bound
at either one prevents cutting at site i, (1 - vi) is replaced by
(1 KjDo &Do)-'. Such anticooperative binding occurs
for the strong sites (GC's) at 101-102 and 103-104 of the
139-mer (Figure 2).
Enhancements in Cleavage Rate. The amount of cutting
at site i, in addition to being proportional to (1 - vi), is proportional to the local concentration of DNase I. If the amount
of DNase I bound to the polymer is small and remains constant
as drug is added, the binding of drug at its binding sites must
redistribute the enzyme to sites where no drug is bound, leading
to enhanced cutting. Evidence for this is the constancy of
"total cut" with drug concentration, the total cut being the sum
of the measured intensities, corresponding to 93% of all
fragments produced by cleavage (see Figure 4). The local
concentration of enzyme, and hence the cutting rate, at a site
where no drug is bound is inversely proportional to the fraction
of the sites on the DNA polymer which are not blocked by
drug (Ward et al., 1988). To take this into account, the local
concentration of probe, the factor (1 - vi), is multiplied by (1
- Kecb)-l,where K, is the enhancement constant and cb is the
total concentration of drug bound on the fragment. The value
of K, can be estimated from the fraction of the sites on the
DNA polymer which are binding sites, but we generally allow
its value to be determined by the minimization of D (see
below).
Of course, the number of DNase I molecules bound to the
fragment cannot remain constant for indefinitely large concentrations of bound drug; eventually, enough drug will be
bound to remove probe molecules from the fragment.
Therefore, the enhancement factor should behave as (1 KeCb)-' only for small cb, but it should increase less rapidly for
large cb, never becoming infinite. It can be shown (Goodisman
& Dabrowiak, 1992) for a simplified situation that the enhancement factor behaves like (1 - Kecb)-' for small cb and
remains ftnite even when all sites are blocked. Since (1 K&b)
behaves like (1 - KeCb)-l for small cb but increases less rapidly
for larger cb, one might use (1 + Kecb) as the enhancement
factor. In the example studied (Goodisman & Dabrowiak,
1992), it is found to work less well than (1- KeCb)-l, but the
truncated power series C;=o(K,cb)' are found to work better.
Spot Intensities. The intensity of the spot on the autoradiogram due to a fragment produced by cutting at site i, when
the drug concentration is c,, is

+

+

+

+

+

+

T i ( C , ) = ki(l - vi)(1 - KeCb)-l
(4)
The tilde refers to a theoretical value; Ii(ct)is the measured
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FIGURE5 : Total-cut plot for the G-labeled experiment. See caption

for Figure 4.

intensity. In the expression for li,ki includes a cutting rate
constant and various proportionality constants, and it is independent of c,. For a site which cannot be blocked by drug
binding (enhancement site), li(c,) = ki(l - Kecb)-l.
The theoretical intensities ji(ct) can now be calculated in
terms of the various parameters: binding constants Ki, enhancement constant K,, and carrier properties c,, c,, K,, and
K,. We determine the values of these parameters by minimizing the mean-square deviation
D = C[Ii(ctj)- Ti(ctj)12
ij

(5)

Here, cti is thejth total drug concentration. The minimization
is performed using the Simplex search technique (Fletcher,
1980).
The totals of the cut-fragment intensities for the A-label
gel (26 values, corresponding to total drug concentrationsfrom
0 to 38.8 pM), plotted in Figure 4, were fitted to a constant
term, to a linear function, and to a quadratic function of drug
concentration c,. Since the linear and quadratic functions gave
no significant improvement in the fit, total cleavage on the
139-mer is essentially constant with added Act-D, justifying
our use of the enhancement model discussed above. The linear
~
line in Figure 4) was used
function 247.1 - 0 . 8 2 5 ~(dashed
to smooth the intensities in the individual footprinting plots
(correcting for errors in loading DNA into the gel, etc.) by
multiplying all I&
for aJ
given c, by (247.1 - 0.825cJ/C,Zi(ct).
The total-cut results for the G-label gel, shown in Figure 5 ,
were treated similarly. The linear fit, J(c,) = 1627.1 - 8.29ct,
was used to smooth intensities for this gel in the way this was
done for the A-label gel, by multiplying all Zj(ct) by J(c,)/

Cizi(4*

For the A-label gel, we rejected data from sites weakly
cleaved by DNase I, retaining data for 54 sites. For the
G-label gel, data for 43 sites were retained. Some of the
footprinting plots used in the analysis for the A-label gel are
shown in Figure 6 (after total-cut correction).
In our previous work (Rehfuss et al., 1990b), we considered
only the strong binding events, using footprinting plots for the
following sites: 54-56, 60, 62-69, 71-72, 85, 87, 98-99,
102-103, 106, 112, 114, 120, 124, 128, 133, 136, 138, 143,
145, and 161. Because the position of the bands is not linear
in site number and because there is not a spot for each band,
assignment of the bands to sites is problematic, especially for
sites above 110, corresponding to larger DNA oligomers,
because resolution decreases. However, the G-labeled fragment, which has the 32Patom on the opposite strand and at
the opposite end of the 139-mer from the A-labeled fragment
(Figure 2), gives a gel for which site resolution is best for the
higher numbered sites, which now correspond to smaller oli-
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gomers. Comparing the gels from the A-labeled and the
G-labeled fragment facilitates indexing of these bands. The
numbering used previously is apparently low by several site
numbers for sites above about 120.
To identify strong binding sites, we found it useful to calculate the initial slopes of the footprinting plots (fragment
intensities vs total drug concentration) and divide the slopes
by the intercepts (intensities for zero drug concentration) to
get “initial relative slopes” (Ward et al., 1988). Stronger
binding sites are easily identified by negative slopes, while
positive slopes characterize weaker or nonbinding (enhancement) sites. The constancy of initial relative slopes over enhancement sites provides further evidence for the validity of
the redistribution-enhancement model (Ward et al., 1988).
Deviations from constancy may indicate drug-induced structural changes in DNA, manifesting themselves in a change
in cleavage rate constant at the site (Rehfuss et al., 1990b).
In the previous analysis (Rehfuss et al., 1990b), sites were
classified as either enhancement or binding sites. Some of the
sites considered as enhancements at that stage (for example,
85,87, 112, 114) are revealed to be influenced by weak-binding
drug sites when results for drug concentrations greater than
7.64 pM are considered. For lower drug concentrations,
however, they behave like typical enhancements, as can be seen
from the goodness of fit by the theoretical enhancementsite
curves (dashed lines in Figure 6). Clearly, examination of
initial relative slopes is not useful when one considers weaker
sites, since intensities for such sites show an initial enhancement
(followed by a decrease in intensity as c, increases further. It
is necessary to consider the entire footprinting plot in order
to classify a site as binding or enhancement.
Role of Carrier DNA. Since appreciable binding to the
weaker sites takes place only at higher drug concentrations,
we modeled the carrier in our previous work (Rehfuss et al.,
1990b) as consisting of only one kind of site, with concentration
c, and binding constant K,, K, representing the average of the
strong binding sites on the carrier. We carried out the minimization of D using several different values of c,, and we found
that the minimum value of D was lowest near c, = 4.7 p M .
The enhancement factor was written as (1 - Kecb)-’,where
cb is the concentration of drug bound to fragment. The value
found for the enhancement constant K , was 4.9 X lo6 M-l.
K, should be equal to the reciprocal of the concentration of
drug-binding sites on the fragment. Since the fragment is 139
base pairs long and each site occupies 7 base pairs, there are
20 sites per fragment; multiplying by the fragment concentration of 1/139 pM should make K, about 20/139 pM-* =
7 x lo6 M-l.
With 19 drug concentrations and 32 sites, the calculation
of the deviation D involved 608 data points. The lowest value
of D (Rehfuss et al., 1990b) was 126, making the rootmean-square deviation d126/608 = 0.46, about the same as
the error in the data points, as judged by their scatter.
However, certain footprinting plots were noticeably less well
fitted than others, indicating inadequacies in the model. The
low-concentration part of the G-label gel was analyzed similarly to the A-label gel. The determined binding constants
for strong sites were in agreement with those from the A-label
gel.
In the present calculations, designed to determine weak- and
strong-site binding constants, we consider footprinting plots
from the A-label gel for all sites for which appreciable intensities are available. We develop the model used to interpret
the A-label gel below, and we derive the strong-site and
weak-site binding constants. Then, the model is used to in-
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terpret footprinting plots from the G-label gel which have
appreciable intensities and to obtain binding constants. Although the data from the G-label gel show a lot of scatter, its
autoradiogram has the best site resolution for the higher
numbered sites, as mentioned above. By comparing the plots
derived from the G-label gel with those obtained from the
A-label gel to check on site numbering, we conclude that the
A-label site numbers are too low by about 3 for sites after
about 120. The original reference numbering is used in the
present paper.
Since we are now dealing with the full range of drug concentrations (to 38.8 p M ) , we must include the additional
parameters c, and K,, representing the concentration and
average binding constant of weak sites on carrier DNA. ”e
enter the determination of the freedrug concentration Do. We
use a value of 5 pM, as found in earlier calculations (Rehfuss
et al., 1990b), for the concentration of strong sites on carrier
and (initially) 13 pM for the weak-site concentrationc, since,
on the fragment, there are about 2l/* as many weak sites as
strong ones. We determine the value of K , in the minimization, along with the strong-site binding constant K,, the
enhancement constant K,, and the site-binding constants for
the fragment.
ANALYSIS:DEVELOPMENT
OF THE MODEL
We now discuss the development of the model as it applies
to the A-label gel data. We are able to use data for 54 sites,
and there are 26 drug concentrations,giving 1404 data points
to be fit. Table I summarizes the behaviors of the 54 footprinting plots used (uncorrected site numbers are given), and
it gives the assumptions of the model used to explain them.
To limit the number of parameters, several unknown weak
binding sites have been assigned the same binding constant,
K,,although one might consider assigning them different weak
binding constants, and K9 has been used to describe the binding
to the sequence CCC at 129-131, even though this binding
constant need not be the same as that for the sequence CCGT
at 123-1 26.
The two GC sites at 101-102 and 103-104 are so close
together that binding of drug at one excludes binding at the
other. This exclusion explains why the intensity for cutting
at site 98 (Figure 4) never decreases to zero (cutting here is
blocked by drug binding at 101-102, which is in turn blocked
by drug binding at 103-104) and why the intensities for sites
99, 102, and 103 decrease more sharply with drug concentration than the intensity for site 106 (they are affected by
binding at either GC site). An attempt to include a similar
kind of exclusion between other nearby weak binding sites (e.g.,
the GGC at 119-121 and the CCG at 123-126) failed: D
increased when the exclusion-binding model was used for sites
in this region. Presumably, drugs bound at these two positions
are not close enough to interfere with each other. We also
tried to put in a second binding constant for the weak sites
in the region 160-165, which is 5’-GCCG-3’, but minimization
of D returned a very small value for this binding constant. This
means that 5’-CG-3’ is so much weaker than 5’-GC-3’ as a
binding site that binding to the former site can be neglected.
Weak Act-D Sites on Carrier DNA. With the carrier-site
concentrationsgiven above, and an enhancement factor of (1Kgb)-’,we minimize the sum of the squared deviations D with
respect to K, and the binding constants on fragment and
carrier. This represents a total of 16 nonlinear parameters.
The binding constants obtained, with c, and c, fixed respectively at 5 and 13 pM, are given in column I of Table 11. The
logarithms of the fragment binding constants K,-K13are given,
followed by the logarithms of the carrier binding constants K,
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Table I: Behavior of Footprinting Plots and Their Interpretation
from the A-Label Gel"
behavior
of spot
intensities

site
no.b

inc with c,
rap. inc with ct
rap. dec
very rap. dec
rap. dec
rap. dec
inc, then dec
inc, then dec
unchanged with
c,, then dec
81, 83
inc, then dec
85, 87
slowly inc
89, 90
inc
inc
92, 94
95
slowly inc
inc
96
98
dec with ct
99, 102 rap. dec with ct
103
rap. dec
106
rap. dec
108
inc
112
inc, then dec
114
inc, then dec
120
unchanged with
ctrthen dec
124
inc, then dec
126
rap. inc
inc, then dec
128
133, 136 dec with ct
138
dec with c,
143, 145 inc, then dec
147
inc, then dec
inc
150
154
inc, then dec
158. 161 inc. then dec
54, 55
56-59
62-66
67
68-69
71-72
75-78
79
80

interpretation
very weak bind., K7
enh
bind. to G C at 63-64; K ,
bind. to GC's at 63-64 and 69-70, K2
bind. to G C at 69-70, K2
bind. to G C at 69-70
bind. to G G C a t 76-78, K ,
bind. to 76-78 and C C G a t 80-82, K4
bind. to C C G a t 80-82, K4
bind. to C C G a t 80-82
unknown weak bind. site, K4
enh
enh
enh
enh
bind. to G C at 101-102, K 5
bind. to G C at 101-102 or 103-104, K6
bind. to G C at 101-102 or 103-104
bind. to G C a t 103-104, K6
enh
bind. to nonclassical site, K7
bind. to G G C a t 119-121, K8
bind. to C C G T at 123-126, K9
bind.
enh
bind.
bind.
bind.
bind.
bind.
enh
bind.
bind.

to C C G T a t 123-126
to
to
to
to
to

C C C a t 129-131, K9
G C at 137-138, K l o
G C a t 137-138
G G C a t 143-145, K l l
G G C a t 149-151, K I 2

to G C a t 160-161, K 1 3
to G C C G G at 160-164. K 1 2

a Abbreviations:
rap., rapid; inc, increase; dec, decrease; bind.,
binding; enh, enhancement. bSite numbers refer to the s q u e n c e shown
in Figure 2. Numbers greater than -110 are probably low by -3.
CAllsequences are 5' to 3'.

and K , (for strong and weak sites), the value of the enhancement constant K, in the factor ( I - Kecb)-l,and the value
of D.
All of the binding constants for strong sites on the fragment
are significantly higher than the corresponding binding constants determined previously (Rehfuss et al., 1990b). The
reason for this is the inclusion of weak binding sites on the

carrier, as is shown by carrying out the minimization of D with
c, reduced from 13 to 0.05 pM (essentially zero). The
fragment binding constants are all reduced, as shown in column
11. (Of course, the value of K , must increase markedly when
the value of c, is reduced markedly.) With a low or zero value
of c,, the maximum concentration of drug that can be bound
to the carrier is 5 pM (the value of cc), so that when the total
drug concentration exceeds 5 pM, the free-drug concentration
rises rapidly with total drug concentration and smaller fragment binding constants are required to explain the measured
binding isotherms. Since D for the low value of c, (calculation
11) is much larger than for c, = 13 pM (627 vs 517), we have
to accept an appreciable value of c, as correct, with the higher
binding constants that result.
To ascertain whether the value of c, can be determined from
the minimization of D and, if it can, what the value of c, is,
we performed minimizations of D assuming c, = 10 and 7 pM.
The results are shown in columns I11 and IV of Table 11. The
values of D from columns I, 111, and IV show a shallow
minimum as a function of c,. Fitting them to a parabola, we
find the minimum at c, = 10.3 pM, with D = 507. In all
subsequent calculations, we maintain c, at 10 pM. It may
be noted that increasing c, leads in general to increases in
fragment binding constants, but that the changes when c,
varies from 7 to 13 pM are small. The binding constant K ,
must of course decrease with increased c,, while K , hardly
changes with c.,
Enhancement Factor. As mentioned above, the enhancement factor (1 - Kecb)-lcannot be correct for large values of
Cb, since this factor becomes infinite for cb = l / K e , whereas
the enhancement should never become infinite (Goodisman
& Dabrowiak, 1992). When (1 + Kecb),which behaves like
(1 - Kecb)-l for small cb and remains finite for all values of
cb, was used for the enhancement factor, the results of column
V of the table were obtained. The resulting binding constants
differ only slightly from those of column 111, but D is much
larger (554 instead of 507),so that the factor (1 - Kecb)-'fits
our data better, and this form of the enhancement is used in
succeeding calculations.
The lowest value of D so far is from calculation 111, D =
507. The root-mean-square deviation is v'[507/(26 X 54)]
= 0.60, which is somewhat greater than our estimate for the
precision of the experimental intensities. Thus, we cannot state
that our model fits the data to within experimental error. This
implies that some effects are not yet included in our model,

Table 11: Effect on Calculated Binding Constants of Weak-Site Concentration on Carrier and Expression Used for Enhancement
calculation
log of
binding
constant

K,
K2
K3
K4
KS
K6

Kl
K8
K9
KI,
K ,1
Kl2
K ,3
Kc
K,
Ke

D

I
c,, = 13 p M ,

(1 - KeCb)-I
6.37
6.01
5.17
5.13
6.05
5.95
4.31
4.97
5.23
6.61
5.35
4.40

5.55
7.13
5.78
7.9
517

x

111

IV

V

c, = 10 pM,

c, = 7 p M ,

c, = 10 pM,

(1 - Kecb)-I
5.60
5.48
4.88
4.92
5.83
5.65
4.23
4.87
5.01
6.01
5.00
4.42
5.16
6.89
7.10

(1 - KeCb)-'
6.15
6.07
5.15
5.18
6.15
5.96
4.41
4.95
5.19
6.60
5.29
4.47
5.46
7.21
5.93

(1

8.2 X lo6
627

8.2 X lo6
507

8.0 X lo6
522

I1

106

c, = 0.05

pM,

- KeCb)-'
6.31
6.01
5.09
5.06
6.01
5.82
4.33
4.94
5.16
6.56
5.19
4.51
5.39
7.01
6.20

( l + K&b)
6.16
6.07
5.11
5.12
6.05
5.97
4.08
4.85
5.20
6.68
5.26
4.35
5.43
6.92
6.12
1.58 x 107
554
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Table 111: Effect on Calculated Binding Constants of Inclusion of
Cooperative Binding and Changed Enhancement Expression

3.2

1

calculation
log of
binding
constant
Kl
K2
K3
K4

K5
K6

K7
K8
K9
KlO
KI I
K12
K13

44
Kc
KW
value of K ,

D
Parameters in
tanh Factor

I
c, = 10 p M ,
(1 - KcCb)-I,
17 parameters
6.17
5.94
5.14
5.16
6.23
6.13
4.33
4.94
5.10
6.63
5.25
4.45
5.46
5.65
7.28
5.92
7.2 X lo6
495

*I
02

03

I1
c, = 10 pM,
(1 - K.&b)-I,

I11
= 10 pM,
C:%dKeCb)',

,C

cooperativity

cooperativity
6.16
5.90
5.00
5.10
6.07
5.90
4.14
4.8 1
4.95
6.48
5.05
4.33
5.27
5.31
7.26
5.82
7.2 X lo6
477

6.16
5.87
4.95
4.89
6.01
5.92
4.17
4.71
4.89
6.43
5.02
4.30
5.24
5.60
7.03
5.61
7.1 X lo6
435

1.71
5.0 X lo7
6.9 X 10"

1.70
4.0 X lo8
5.9 X

for example structural changes. Sites for which the fit of
theoretical to experimental footprinting plots is worst at this
stage are 78, 87, 112, 128, and 147.
The solution to the problem for site 128 has already been
noted: cutting at this site is inhibited by drug binding at the
CCC sequence located at base pairs 129 to 131, and the drug
binding constant for this sequence may be different from K9,
which describes drug binding to the CCG sequence located
at 123-125. By including an additional constant K,, to describe drug binding to the CCC, we minimize D with respect
to 17 nonlinear parameters, obtaining the results in column
I of Table 111. We note a reasonable improvement in D,from
507 to 495, when the additional parameter is inserted; values
of other parameters are not changed much.
Increased Binding. Comparison between theory and experiment shows that, in general, the footprinting plots calculated from our model for binding sites do not decrease sharply
enough with total drug concentration for concentrations near
20 pM. Correspondingly, footprinting plots calculated for
enhancement sites do not increase sharply enough in this region. Apparently, there is a rather rapid increase in the
concentration of drug bound to the weak sites on the fragment
when the total drug concentration increases past 20 pM.
(Because intensitiesfor cutting at sites blocked by drug binding
at strong sites are already near zero at this point, no information is available about the amount of drug bound to strong
sites.) This could be due to a structural change in the fragment
induced by the bound drug or to cooperative binding. It may
be noted that there is a sudden (although relatively small in
magnitude) drop in total cut (Figure 4) after [Act-D] = 20
pM. This affects the correction factors used in the total-cut
smoothing, but this cannot cause both sharp increases and
sharp decreases in individual footprinting plots; these are
present in the unsmoothed plots.
We model the increase in the effective drug binding constant
by multiplying each binding constant Ki ( i = 1-14) by the
same function of bound drug concentration:
Kieff = Kj(al

+ (ai - 1) tanh [az(cb-a3)])

(6)

FIGURE7: Increased binding factor, K t f f / K i(eq 6), which multiplies
binding constants to give effective binding constants, as a function
of the bound drug concentration. Optimum (minimum 0 )values of
the parameters are used.

According to the above function, the effective binding constant
is Ki in the absence of bound drug, when cb, the calculated
concentration of drug bound to the fragment, is much less than
a3. It becomes (2a1- l)Ki when cb is much greater than u3,
the parameter a2 giving the sharpness of the change. With
eq 6 , three new parameters are introduced, making the total
number 20. As shown in column I1 of Table 111, there is a
small but significant improvement in the fit.
The enhancement factor for binding (eq 6 ) is plotted as a
function of cb in Figure 7, using the best values of the parameters a l , u2 and a3. For the five highest total drug concentrations (20.3, 23.8, 28.0, 33.0, and 38.8 pM), cb is calculated as 0.059, 0.075,0.080,0.084,and 0.087 p M , respectively. Then, the enhancement in binding occurs mostly between total drug concentrations of 20 and 24 pM,which is
where the sharp intensity decreases occur. In fact, D is found
to be insensitive to the value of a2. This is because we know
only that most of the increase in drug binding (by a factor of
2.4) occurs between 20 and 24 pM,so that a2(24-20) pM must
be much larger than unity, and a2 >> 2.5 X IO5 M-I.
On studying the observed and calculated footprinting plots,
we observe one remaining problem: calculated plots for enhancement sites show intensities which rise sharply with total
drug even for the highest drug concentrations, whereas the
experimental intensities apparently level off. This is related
to the fact mentioned above that (1 - Kecb)-I,which becomes
infinite for cb = l/Ke, cannot be the correct enhancement
factor for large cb, but only for small cb. Functions behaving
like (1 - Kecb)-l for small cb but increasing less for large cb
are the power series' c&o(Kecb)-lfor finite values of n. The
linear function (n = 1 ) has already been tried and found
unsatisfactory (column V, Table I). After some experimentation, we chose n = 10, although the exact value of n is not
critical; the results, which include a significant decrease in D
from n = 0,corresponding to (1 - & , ) - ' ,are given in column
I11 in Table 111.
D is reduced to 435 and the root-mean-square deviation is
now v'[435/(54 X 26)], or 0.56. The footprinting plots now
seem to reproduce the experimental ones quite well, with a
few exceptions (see Figure 6 ) . To improve our model by
increasing the number of variable parameters would be unjustified and would require more work, with probably little
decrease in D. The three parameters in eq 6 already have little
chemical basis except that they produce the increased binding
shown by the data. Note that the various improvements in
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Table IV: Binding Constants of Act-D on the 139-mer (XIO-s M)
position"
sequence
A-label gel
G-label gel
62-65
TGCT
35.0
4.8
68-71
CGCA
18.0
76-79
GGCA
2.1
1.3
80-83
CCGT
1.8
1.7
100-103
TGCG
25.0
22.0
102-105
CGCT
20.0
8.8
various
various
0.3
118-121
CGGC
1.2
0.3
123-126
CCGT
1.8
0.9
128-1 3 1
ACCC
9.4
4.8
136-139
TGCT
64.0
30.0
143-1 46
GGCA
2.5
2.0
149-152
GGCT
0.5
0.8
159-162
TGCC
4.2
4.5
"Site numbers refer to the sequence in Figure 2.
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Table V: Behavior of Footprinting Plots and Their Interpretation from the
G-Label Gel"
behavior
of spot
site no.b
intensities
interpretation
47, 49, 56 inc with ct
enh
65
rap. dec
strong bind. to GC at 63-64; K,'
75
inc, then dec
bind. to GGC at 76-78, K,'
82, 84
level, then dec
weak bind. site, K i
93,95
inc
enh
101
rap. dec with ct
bind. to GC at 101-102, K i
105
rap. dec
bind. to GC at 101-102 or 103-104, K{
110
inc with c,
enh
119
inc, then dec
bind. to GGC at 119-121, Kd
122
inc, then dec
bind. to GGC at 119-121
123-126
inc, then dec
bind. to CCGT at 123-126, K,'
127, 128
inc, then dec
bind. to above and CCC, 129-1 3 1
130-132
inc, then dec
bind. to CCC at 129-131, K,'
134, 135
dec with ct
bind. to CCC at 129-131
136-141
dec with ct
bind. to GC at 137-138, K{
142
inc, then dec
bind. to GGC at 143-145, KId
144, 146
inc, then dec
bind. to GGC at 143-145, K I d
148
level, then dec with ct bind. to GGC's at 143-145, 149-151
149-150
level, then dec with ct bind. to GGC at 149-151, KI1'
152, 153
level, then dec with ct bind. to GGC at 149-151
154
inc with c,
enh
158
inc, then dec
bind. to GCCGG at 160-161, K , {
"Abbreviations: rap., rapid; inc, increase; dec, decrease; bind., binding; enh,
enhancement. bSite numbers refer to the sequence shown in Figure 2. CAll
sequences are 5' to 3'.

*
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our model, while lowering D significantly, have had little effect
on the calculated values of the binding constants for fragment
sites. Thus, further changes in our model will probably not
9
change the ICs much. The binding constants for our best
calculation (lowest D) are given in Table IV.
*
Footprinting with G-Labeled 139-mer. We now consider
0"
I .
,
P
6
12
18
24
30
30
42
48
5
4
d0
the data from the G-label gel, analyzing it by the model de[Actinomycin], PLY
veloped for analysis of the A-label gel. This means that we
FIGURE 8: Footprinting plots from the G-label gel, after total-cut
use the same values for the concentrations of strong and weak
smoothing. Symbols are measured spot intensities; broken curves are
sites on the carrier rather than determine the best values for
fits calculated from the model. In the top plot, *, 0 , and 0 are for
these concentrations by minimization of the mean-square
sites 84, 101, and 110; in the middle plot, *, 0 , and 0 are for sites
deviation D. For the enhancement factor, we use ~ , ! ~ o ( K e ~ b ) - l ,122, 127, and 135; in the bottom plot, *, 0 , and 0 are for sites 138,
148, and 154.
and no correction for cooperative binding is included.
Intensities for nine actinomycin concentrations (2.4, 3.4,4.9,
6.9, 9.9, 14.1, 20.2, 28.7, and 40.9 pM) plus two controls were
apparent large changes in intensities for some sites near 20
used. Having two sets of intensities for zero drug concentration
pM drug concentration.
allows an assessment of the error in the intensities. In general,
We used data for all sites for which intensities were apthe data from the G-label gel show more scatter than those
preciable and the fluctuations were significantly smaller than
from the A-label gel. This is evident in the plot of total cut
the intensities themselves. This means that 43 sites were
vs drug concentration (Figure 5 ) . The linear fit to the total-cut
considered, as listed in Table V, and 473 total data points.
plot, 1627.1-8.29ct, was used to smooth intensities, as discussed
Table V indicates how each footprint was modeled. Note that
above for the A-label gel. There appears to be a drop-off in
the Ki'for this gel do not always correspond to the Kifor the
the total cut at a drug concentration of 20-24 pM, as in the
A-label gel.
A-label gel. Several footprinting plots are shown in Figure
There are a total of 15 parameters in this model: 12 binding
8. The scatter in the data should be noted, as well as the
constants on the fragment, the strong- and weak-site binding
I I I I

I ? I I I I I I I . I

I

I I

I

I

I II I I

II

b I I I
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constants on the carrier, and the enhancement constant K,.
Minimization of D with respect to these parameters gives a
value of 1.03 X lo4. Dividing by 473 and taking the dquare
root gives a meari-square deviation of 4.7, which seems slightly
bigger than the fluctuations in the data points. The carrier
binding constants were found to be 89.3 X IO5 and 8.9 X lo5
M-' for the strong and weak carrier sites, and the enhancement
constant was 7.7 ,X lo6 M-l.
The values of the fragment binding constants are given in
Table IV. Note that, for this gel, resolution is low and site
numbering is uncertain for the lower numbered sites. This
probably accounts for the constant for the first site being much
lower than that calculated from the A-label gel: spots for the
single-site 65 considered to be responding to binding to the
GG at 63-64 were actually superpositionsof spots arising from
cutting at several sites. Thus,the value of this binding constant
is very poorly determined from the G-label gel. Similarly, the
constants for the overlapped sites having GC's at 101-102 and
103-104 were determined from data from only two footprinting plots, as compared to five on the A-label gel, so one
cannot put much confidence in the smaller value. On the other
hand, the value found for the binding constant for the site
having GC at 137-138 is probably more reliable from the
G-label than from the A-label gel because six footprinting plots
were used in the former case and only three were used in the
latter.
Summary. It was assumed that when a molecule of actinomycin D is bound to DNA, it blocks about 7 base pairs from
cleavage by the probe DNase I. The size of the inhibition
region follows from the structures of the drug and probe as
well as from previous footprinting work on this system. In
setting up our model, we must decide which drug-binding
events, if any, affect cleavage at each site for which we have
a footprinting plot. A consistent picture could only be made
if the numbering of the footprints for the A-label gel was
urlderstood to be too low by about 3 base pairs for sites after
about 110, where the numbering for the A-label gel becomes
uncertain. That the original numbering was incorrect in this
way was confirmed by observation of footprinting data obtained from G-labeled fragment, for which assignment was
more accurate for the higher numbered sites.
The binding of drug to a site on DNA is governed by the
simple chemical equilibrium
(7)
where Kiis the binding constant (whose value our analysis
attempts to derive), ci is the concentration of fragments which
have drug bound at site i, c is the total concentration of
fragments (so c - ciis the concentration of fragments having
no drug bound at site i ) , and Do is the concentration of free
or unbound drug. Where two strong binding sites are adjacent,
drug binding at one prevents drug binding at another and eq
7 must be modified. The free-drug concentration is related
to the known total drug concentration c, by
Ct

= Do

+ cb + ,C

(8)

where cb is the concentration of drug bound to the fragment
(cb = C,ci)and c, is the concentration of drug bound to sites
on the carrier DNA. The value of c,,, which was expected
to be much larger than cb because there was about 200 times
more carrier than labeled fragment, was determined by
equilibria like that in eq 7. For simplicity, we assumed that
carrier sites could be represented by two kinds: strong sites
of concentration c, and binding constant K,,and weak sites
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of concentration c, and binding constant K,. This leads to
eq 3.
By solving all the equilibrium equations simultaneously, we
determined ci for each site i and for each c,. For any cleavage
site within the inhibition region of drug site i, the probability
that cleavage can occur is the probability that no drug is bound
at site i, 1 - ci/c. Some cleavage sites may be blocked by two
independent drug-binding events; if the drug sites are j and
k, the probability of cleavage is (1 - c,/c)(l - c k / c ) .
In addition, we noted that if bound drug prevents cleavage
at some sites on a fragment by blocking access of the enzyme
to part of the DNA, the concentration of enzyme at other
places on that fragment, where no drug is bound, should increase. Thus, the cleavage rate, which is proportional to the
local concentration of enzyme, should increase at those places.
This is the origin of the enhancement factor, which multiplies
all intensities. The factor was written as E = (1 - &&)-I,
where K, is a constant and cb is the concentration of drug
bound to fragment, or as a finite power series, &,(K,Cb)',
Finally, at total drug concentrations high enough for appreciable binding to the weak sites, we noted an abrupt decrease
in amounts of cleavage products with drug concentration. This
is modeled by multiplying all binding constants by an increasing function of cb (eq 6). The values of the parameters
in this function are determined, along with the binding constants to 139-mer and carrier and the enhancement constant
K,,by variation.
We found the set of values of the parameters which minimized the sum of the squared deviations between calculated
and experimental intensities:

D = C(li(ctj)- zLct,)I2

(9)

i,

Here, Zl(ct,) is the measured intensity or amount of fragment
resulting from cleavage at enzyme site i when the total drug
concentration is ct, and Ti(ct,) is the corresponding intensity
calculated from our model. The measured cut-fragment intensity is proportional to the probability of cleavage. For the
A-label gel, there were 54 footprinting plots, each corresponding to a particular cleavage product, and 26 drug concentrations, giving 1404 points. Our best calculation involved
20 nonlinear parameters and led to D = 435. The rootmean-square deviation was the same size as the fluctuations
in measured intensities from point to point.
DISCUSSION
In this article, we present measured footprinting plots for
actinomycin D binding to DNA, as well as the model and
analysis which allow us to derive binding constants for strong
and weak sites, as well as other parameters. This is the only
quantitative footprinting study of which we are aware which
deals simultaneously with such a large number of footprinting
plots and such a large number of ligand concentrations. The
model involves the same assumptions as did models used in
previous work (Ward et al., 1988; Rehfuss et al., 1990b), but
modifications were necessary to take into account the behaviors
of the footprinting plots revealed at high drug concentrations.
The footprinting plots f,(c,,) calculated from our model reproduce the behavior of the observed footprints quite well in
general (see Figure 6 ) . A measure of the experimental error
or scatter in the intensities is obtained from deviations from
the expected continuous variation of intensity with drug concentration, as estimated by fitting a line through several points,
and is about 0.5 unit.
However, there are exceptions, identified by inspection of
the footprinting plots, examples of which are shown in Figure
6 , or by calculation of the contribution of each site to D sites
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59, 106, 108, 124, 126, 136, 143, and 161. For sites 108 124,
126, 136, and 161, the problem seems to be in the experimental
intensities themselves, which vary irregularly with concentration. Site 59 is modeled as an enhancement, whereas the
spot intensity actually remains roughly constant with drug
concentration for concentrations up to 20 pM and then increases rapidly to a new constant value approximately double
the first. The only nearby drug-binding site is the GC at base
pairs 63-64, which is a strong site, giving binding-type plots
for sites 62-65. Possibly, the special behavior of site 59 is
associated with its being on the boundary of the inhibition
region for this binding site. The data for site 106, which is
modeled as responding to drug binding to the GCGC at
101-104, can be better fit by a curve (see Figure 6) such as
those for sites 85 and 87, which were assumed to be showing
inhibition due to a very weak and unspecified binding site (K
= 3 X lo4). However, site 108 appears to be an enhancement
site, so it is difficult to postulate a weak site to which 106 could
respond.
Sites 143 and 145 are modeled as responding to binding at
the GGC at 143-145. However, experimental intensities seem
to drop much more abruptly near 20 pM, before leveling off,
for site 143 than for site 145. This cannot be explained with
our model, unless it simply reflects large errors in the experimental intensities. Also, as noted previously (Goodisman
& Dabrowiak, 1991, 1992), many footprinting plots show a
small rapid decrease in intensity with total drug concentration,
followed by an increase, near 2 pM. Examples in Figure 6
are sites 85, 87, and 89. This behavior cannot be explained
in the context of the present model. We have investigated
(Goodisman & Dabrowiak, 1992) whether this indicates a
structural change in the DNA like that suggested by other
workers (Fox & Waring, 1984; Huang et al., 1988; Bishop
et al., 1991).
Values of Parameters. We now consider the values of the
parameters determined by the minimization process. According to our model, the enhancement E at sites where no
drug is present is due to the increased probe concentration
there, caused by drug at the other sites, so that E should be
inversely proportional to the fraction of the total number of
probe sites available. The concentration of probe sites (base
pairs) is about 1 pM. Letting cb be the molar concentration
of drug bound to the 139-mer and assuming each drug blocks
seven base pairs, we have
E = 10-6/ (10-6 - 7cb)
If this is written as (1 - K,cJ1, we find K, = 7 X lo6, close
to what is determined by minimization. In previous work
(Ward et al., 1988), we noted larger enhancements at sites
adjacent to (strong) drug-binding sites. Now that many
footprinting plots previously considered to be enhancements
are seen to respond to weak binding sites, only a single site,
96, appears to show this effect (GC is found at 101-102).
The carrier, calf thymus DNA, is modeled as having two
kinds of sites: the strong sites are given a concentration of
5 pM, as determined from previous calculations which considered strong sites only, and the weak-site concentration is
determined as 10 pM from a series of calculationsto determine
the value that makes D smallest. These values are reasonable,
although perhaps low, since the 139-mer contains about 6
strong sites and 11 weak sites in 137 base pairs and the concentration of carrier is 190 FM. The binding constants for
strong and weak sites on carrier were determined by minimization of D as 1.1 X lo7 and 4.7 X lo5. That these values
are higher than the average strong- and weak-site binding
constants on the fragment may be due to the carrier-site
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concentrations being too low. Using higher values for these
concentrations will decrease the carrier binding constants and
decrease the binding constants for the fragments, but only
slightly.
The use of carrier DNA makes it unnecessary to determine
the concentration of radiolabeled fragment precisely, which
would be difficult, but it also complicates the analysis. Since
the structure of the carrier DNA is different from that of the
radiolabeled fragment, only a fraction of the individual loading
events taking place in the system are seen on the sequencing
autoradiogram. However, other analyses have shown that a
simple model of drug binding to the carrier is sufficient to
obtain reliable site-specific binding constants toward the
fragment. For small oligonucleotide duplexes which possess
a single drug-binding site and which are readily available,
unlabeled duplex may be used as the carrier. Then, quantitative analysis of footprinting data is simplified since the only
loading event taking place is observed on the sequencing autoradiogram, and there are fewer parameters to determine.
As it becomes easier to purify significant amounts of DNA
restriction fragments, it will be more practical to use the
unlabeled fragment as carrier. This will be advisable since
it ensures that most (not all) of the loading events are seen
on the autoradiogram, making the modeling of unobserved
events less important.
Binding Constants. The binding constants for Act-D at
specific sites on the 139-mer are given in Table IV. Calculated
values for log K, are probably reliable to 0.1 in most cases,
which means Ki is good to 25% and the free energy of binding
to 0.6 kJ/mol. Values of Ki for the G-label gel are generally
less reliable because there is more scatter in the data. The
value for the site at 62-65 is particularly uncertain because
the site is in a poorly resolved region of the gel and because
only one footprinting plot is used in its determination. As
discussed above, the binding constant for the CGCT at
102-105 is much better determined from the A-label gel than
from the G-label gel, while the reverse is true for the TGCT
at 136-139. Aside from these cases, binding constants derived
from analyses of the two gels generally agree.
The binding constants are generally higher than what we
reported in previous work on this system (Rehfuss et al.,
1990b), which analyzed only footprinting data at low drug
concentrations, but the order of binding constants is not
changed. As shown above, the reason for larger binding
constants now is that previous work neglected the weak carrier
sites, using a total carrier-site concentration of only 5 pM.
Then, the carrier is saturated with drug when ct gets much
past 5 pM, and the free-drug concentration rises rapidly with
total drug concentration.
The strong sites, with binding constants greater than lo6
M-I, all possess the 5’-GC-3’ sequence without a preceding
G, and every such sequence within the region of the fragment
for which we have footprinting data is a strong binding site,
except possibly the 5’-TGCCGG-3’ at sites 159-164 (K = 4
X lo5 M-I). The binding constant for this last site may appear
low because the site is close to the end of the measurable region
of the gel, making the experimental data unreliable. More
likely, it is low because the sequence is 5’-GCC-3’ on the coding
strand and therefore 5’-GGC-3’ (a typical weak binding site)
on the noncoding strand.
The highest binding constant we find on the fragment is 6
X lo6 M-l, for the sequence 5’-TGCT-3’at 136-139. However,
the site at 62-65, which has the same sequence, has a binding
constant of only 4 X lo6 M-l. This indicates that bases
flanking the tetramer are important in the interaction. Since
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the drug can span only 4 base pairs of DNA, it is implied that
Act-D affinity may be affected by changes in DNA structure
induced by the bases flanking the tetrameric contact sequence.
Flanking bases may also influence the binding of Act-D to the
sequence CGCT. On the 139-mer, the 5’-GCGC-3’ sequence
(sites 101-104) has a binding constant of about 2 X lo6 M-’
(Table IV), whereas quantitative footprinting studies of Act-D
binding to the fragment d(TAGCGCTA)2 (Rehfuss et al.,
1990) return a binding constant of about 4 X lo6 M-l. The
difference may also be the result of end effects associated with
short segments of DNA compared to polymeric DNA.
The site in the vicinity of 130 on the fragment, with sequence
CCC, is also a relatively strong binding site, with K = 9 X
lo5 M-’ (this value is somewhat more uncertain than others
because it comes from data for only one cleavage product).
Unlike the examples above, it does not possess a core sequence
having a C, axis of symmetry, like GC, and it is difficult to
see how the drug, which has a pseudo-C2 symmetry axis,
interacts with the sequence. In the classical model for binding
to GC, the two threonine moieties of the drug hydrogen bond
to the 2-amino groups of both guanines at the intercalation
site. The fact that CCC is a strong binding site was previously
noted in studies with 7-azidoactinomycin D, which is able to
photocleave DNA (Rill et al., 1989).
The weak sites, with binding constants between 0.5 X lo5
M-’ and 9 X lo5 M-’, mostly have the 5’-GGC-3’ sequence.
Exceptions are the “nonclassical” sequences near 80-84 and
123-126, discussed below. The reason for the weak binding
at the GGC sequence is unknown, but it may be related to the
enhanced stacking interactions of the GG doublet, which reduces the ability of the drug to intercalate at the adjacent GC
site (Ward et al., 1988). Previous footprinting studies (Ward
et al., 1988) and studies of cleavage by 7-azidoactinomycin
D (Rill et al., 1989) also showed that GC doublets were
strongly preferred only if the 5’-flanking base was a pyrimidine
and the 3’-flanking base was not cytosine.
The two weak sites near positions 81 and 124 bind drug but
do not have a GC core. It is difficult to identify exact interaction sequences from the footprinting data, but the sites
both have CCGT and Snyder et al. (1989) have shown that
Act-D binds with a high binding constant to the duplex d(CGTCGACG)2. However, the CG sequence at 109-110
shows no tendency to bind Act-D. The sequence CG has 2-fold
symmetry like GC and thus might hydrogen bond to appropriate sites on the pseudo-2-fold symmetric drug, but this
would involve reorientation of its cyclic pentapeptide rings
relative to the phenoxazone chromophore of Act-D if the
2-amino groups of guanine are used as sequence determinants.
The relative orientations of the peptide rings of the drug
outside of DNA are stabilized by specific hydrogen bonds
between the rings (Ginell et al., 1988), which might prevent
reOrientationof the peptide ring in DNA, discouraging binding
of the drug to CG. Like CG, the isolated CC sequence (sites
115-1 16) shows little tendency to bind drug although CCC
binds strongly. This suggests that the CGT triplet is required
for binding.
CONCLUSIONS
In this work, we study the binding of the anticancer drug
actinomycin D to a restriction fragment using quantitative
footprinting methods. We develop the model which allows
calculation of theoretical footprinting plots (intensity of each
spot on the footprinting autoradiogram as a function of drug
concentration), taking into account equilibria between unbound
drug and drug bound to sites on the fragment and on calf
thymus DNA carrier, as well as the enhanced cleavage at sites
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where no drug is bound. A simple model for this mass-action
enhancement is given. Parameters such as binding constants
of drug to fragment and carrier sites (Table IV) are determined by minimizing the deviation between theoretical and
experimental footprinting plots. The binding constants for
Act-D sites on a 139-base-pair restriction fragment are determined. The highest affinity sites have the dinucleotide
sequence GC, and of these, those having the sequence TGCT
have the highest binding constants. Sites having the dinucleotide sequence GC preceded by a G have binding constants in the range (1-4) X lo5 M-I, about 1 order of magnitude lower than those of the strong sites. Certain sites which
do not contain the sequence GC, e.g., CCG and CCC, also
bind Act-D with a binding constant comparable to those of
the weak GGC sites.
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ABSTRACT: In footprinting experiments, an increase in D N A cleavage with addition of ligand to a system

may be due to a ligand-induced structural change. Ligand binding also enhances cleavage by displacing
the cleavage agent from ligand-binding sites, thus increasing its concentration elsewhere. The theory and
characteristics of this mass-action enhancement are given, and it is shown how it may be recognized. Results
of DNase I footprinting of small oligomers, with actinomycin D as ligand, are analyzed to reveal which
enhancements are due to mass action, and which can reasonably be ascribed to structural changes. Patterns
in the footprinting plots from our experiments on actinomycin D binding to a 139-base-pair DNA fragment
(with DNase I as a probe) are studied in the same way. The likely origins of these patterns are discussed,
as are enhancements occurring with other probes commonly used in footprinting experiments.

%e binding of drugs and other ligands may induce structural
changes in DNA, which may be detected by a number of
techniques. Since the rate of cleavage at a particular bond
by agents such as DNase I depends on the local DNA structure
(Lomonosoff et al., 1981; Drew, 1984; Suck et al., 1988), a
natural way to study such changes is the footprinting technique. In a footprinting experiment, one measures the amounts
of DNA fragments of different lengths produced by a cleavage
agent, and hence the amount of cutting taking place at various
positions on a DNA oligomer, as a function of the ligand
concentration (Dabrowiak & Goodisman, 1989; Dabrowiak
et al., 1991). The amount of cutting at positions at or near
ligand binding sites on DNA will decrease with ligand concentration because the bound ligand prevents the approach of
the cleavage agent (inhibition), but, at other positions, one
might expect to see changes in cutting rate due to structural
changes in the DNA. It should be noted that ligand-induced
structural changes may lead to increases or decreases in the
observed cutting rate. Thus, Low et al. (1984) observed large
enhancements in cutting by DNase I and DNase I1 at many
sites on a 160-base-pair DNA fragment when echinomycin
was allowed to bind, in addition to inhibition of cutting near
the drug binding sites (having the sequence CpG). These
authors noted two possible explanations for the enhancements:
structural changes in DNA and an attractive interaction between the cleaving protein and the antibiotic, leading to increased concentration of the former near antibiotic-binding
sites. They were able to dismiss the latter explanation.
However, it is now clear (Ward et al., 1988; Dabrowiak &
Goodisman, 1989; Dabrowiak et al., 1991; Portugal, 1989) that
there is a third explanation for rate enhancements in DNase
I footprinting experiments. Increased cutting at sites where
no ligand binds can arise from a mass-action effect, caused
by the bound ligand displacing the cleavage agent away from
some regions of DNA, and thus increasing the concentration
t We ackowledge the American Cancer Society, Grant NP-681, for
supporting this research.

of cleavage agent elsewhere. This means that one may not
automatically interpret cleavage rate enhancements as ligand-induced structural changes, since the mass-action effect,
due to the equilibrium between DNase I and DNA, is always
present. Since mass-action and structural effects may exist
simultaneously (Portugal, 1989; Ward et al., 1988), one must
always consider whether observed enhancements can be explained by mass action alone or if they are the result of a
structural change as well.
Below, we give a model for the mass-action enhancement
and discuss how one can judge whether enhancements observed
in a footprinting experiment have a structural origin. Then,
we consider observed enhancements on small DNA oligomers
and longer fragments, previously noted by other workers, which
may be due to structural changes or mass-action effects. The
experimentally observed intensity enhancements for actinomycin D interacting with a 139-mer that we believe to be
structural in origin are then presented and discussed.
EXPERIMENTAL
PROCEDURES
The quantitative footprinting studies involving actinomycin
D, the 139-base-pairHindIIIINciI restriction fragment of pBR
322 DNA, and DNase I were as earlier described (Ward et
al., 1988). The sequence of the restriction fragment and the
location of strong and weak actinomycin D binding sites are
shown in Figure 1. Autoradiographic spot intensities, corresponding to relative amounts of 54 cleavage products of
different lengths, were measured for 26 actinomycin D concentrations ranging from 0 to 38.8 pM.
The model used to interpret the resulting footprinting plots,
plots of spot intensity as a function of total drug concentration,
is described in detail elsewhere (Goodisman et al., 1992). The
analysis takes into account binding of drug at the various
binding sites, the mass-action enhancement, and binding of
the drug to unlabeled carrier DNA (calf thymus). Correct
description of the carrier, described as a concentration of strong
binding sites and a concentration of weak binding sites, is
important, since it is mainly the equilibria between drug and
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